Atomwise startup aims to become the key AI partner for pharma and biotech

| By | AI, Drug Development

Atomwise Inc., the creator of AtomNet, the first Deep Learning technology for novel small molecule discovery raised $45 million of growth funding, led by Monsanto Growth Ventures, DCVC, and B Capital Group, in support of its mission to become the preferred artificial intelligence partner for the world’s leading pharmaceutical, biotech, and agrochemical companies.

Atomwise startup, based in San Francisco, USA, showed strong business growth over the past two years. A Silicon Valley software company has struck partnerships with four of the top-ten U.S. pharma companies, multiple biotech firms, and over forty major research universities. Atomwise has over fifty distinct molecular discovery programs and its approach demonstrates a new model for a pharmaceutical industry.

Groundbreaking AtomNet drug research technology learns like a human chemist, using powerful deep learning algorithms and elastic supercompute platforms to analyze millions of potential medicines each day. Aside from a massive increase in discovery productivity, AtomNet also provides greater understanding of the toxicity, side effects, mechanism of action, and efficacy of a drug, far earlier than typical in a drug pipeline. This ability provides Atomwise customers an exponential reduction in the cost and risk of drug discovery.

SOURCE: atomwise
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.